US equities |
NVDA $239.68 ▲+2.45% SPCX $169.35 ▲+6.54% MU $1,060.82 ▼-1.31% TSLA $380.80 ▲+2.76% SNDK $1,688.95 ▼-1.80% MSFT $528.33 ▲+2.09% INTC $116.33 ▼-2.51% META $742.53 ▲+1.98%
FinancialContent

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

18.58 +0.01 (+0.05%)
Delayed Quote Updated: 3:11 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
Ingrid Zhang, an accomplished global biopharmaceutical leader, joins Legend Biotech following a comprehensive Board-led search process 
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech (NASDAQ:LEGN) Q1 2026 Revenue Surges on CARVYKTI Growth, but EPS Falls Short ↗
Via Chartmill
News headline image
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗
One of J&J's investments stands head-and-shoulders above the rest. 
Via The Motley Fool
News headline image
Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript ↗
CARVYKTI sales surged 50% globally as company swung to profitability. 
Via The Motley Fool
Topics Earnings
News headline image
Legend Biotech Q2 Earnings Call Highlights ↗
Legend Biotech (NASDAQ:LEGN) reported second-quarter 2026 results marked by continued global growth for CARVYKTI and the company’s first quarter of company-wide profitability on both an IFRS and... 
Via MarketBeat
Topics Earnings
News headline image
Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Announces CEO Transition
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
2 Biotech Stocks Worth Buying Before Their Potential Buyouts ↗
It has been a banner year for biotech buyouts, and these are two of the prime targets. 
Via The Motley Fool
News headline image
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
Industry Veteran Brings More Than Three Decades of Biopharmaceutical Development and Clinical Operations Experience to Help Guide Pipeline Advancement 
From Calidi Biotherapeutics, Inc
Via GlobeNewswire
News headline image
Legend Biotech Corporation Announces Pricing of Public Offering
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Corporation Announces Proposed Public Offering
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
From Legend Biotech USA Inc.
Via GlobeNewswire
Keep an eye on the top gainers and losers in Tuesday's session. ↗
Via Chartmill
News headline image
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Legend Biotech Conference Spotlights CARVYKTI’s Curative Potential, Earlier Use ↗
Legend Biotech (NASDAQ:LEGN) used an investor and analyst event to highlight long-term data and physician perspectives supporting broader use of CARVYKTI, its BCMA-directed CAR T-cell therapy for... 
Via MarketBeat
News headline image
Legend Biotech Announces Presentations at ASCO 2026
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals ↗
Legend Biotech develops cell therapies for cancer, with a pipeline spanning hematologic malignancies and solid tumors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
With YMM Down 29%, First Beijing Bought 13 Million More Shares ↗
Full Truck Alliance is a top digital freight platform in China, connecting shippers and truckers through tech-enabled logistics services. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Legend Biotech (LEGN) Q1 2026 Earnings Transcript ↗
Legend Biotech (LEGN) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Legend Biotech Q1 Earnings Call Highlights ↗
Legend Biotech (NASDAQ:LEGN) reported sharply higher first-quarter 2026 sales for CARVYKTI, its CAR T therapy for multiple myeloma, as management said demand continued to move into earlier lines of... 
Via MarketBeat
Topics Earnings
News headline image
Legend Biotech Reports First Quarter 2026 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
News headline image
Is Yum China a Buy After Investment Firm Matthews Purchased Shares Worth $12.57 Million? ↗
Yum China operates thousands of quick-service and casual dining restaurants across China under well-known international brands. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Matthews Just Slashed Its Futu Position -- Here’s Why That Matters ↗
Futu Holdings delivers digital brokerage and wealth management services to retail and institutional clients across Asia and global markets. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >